Xerostomia management strategy addresses dry mouth from reduced saliva reducing palatability and increasing infections. Salivary substitute products restore moisture temporarily. Salivary gland stimulation through chewing enhances production. Pilocarpine activates muscarinic receptors increasing flow. Preventive strategies minimise gland exposure.
Clinical monitoring detects severity progression. Supportive care addresses comfort and infection prevention. Regulatory submissions address xerostomia risks. Patient counselling emphasises oral care. Post-approval surveillance identifies xerostomia patterns.
General Biopharmaceutical Concepts
Xerostomia Management Strategy
Xerostomia management strategy comprises therapeutic and supportive approaches to relieve dry mouth and improve oral health and patient comfort.
Continue Exploring
Browse over 900 biopharmaceutical terms across biologics, ADCs, cell & gene therapy, CMC, clinical development and manufacturing.
Browse Glossary →